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Abstract 
Plasmids of incompatibility group (Inc) HI1 are important vectors of antibiotic resistance in both of the major causal agents of 
enteric fever: Salmonella enterica subspecies enterica serovar Typhi and S. Paratyphi A. In S. Typhi, IncHI1 plasmids appeared 
in the 1970s and spread globally. In some circumstances they are maintained within the bacterial population even in the 
absence of selection from antibiotics. The low cost associated with IncH plasmids in Salmonella is due, in part, to the presence 
of a plasmid gene encoding an H-NS-like global regulator which acts co-operatively with chromosomally encoded H-NS. Very 
recently, IncHI1 plasmids have crossed from S. Typhi into S. Paratyphi A; the acquisition of drug resistance and possibly other 
phenotypic traits encoded by IncHI1 plasmids has increased the virulence potential of this neglected pathogen. There is no 
vaccine for S. Paratyphi A and resistance to the current drugs of choice, the fluoroquinolones, is also spreading rapidly. There is 
a conserved backbone to all IncH plasmids but variation occurs in regions of the plasmids associated with antibiotic resistance. 
These IncHI1 plasmids are allowing major human pathogens to sample genes available in their environment, the human gut, 
and will be maintained by enhancing the competitive advantage of the bacterial host. Therefore competition between closely 
related resistance plasmids will probably increase the transmission of enteric fever by enhancing the fitness of their bacterial 
hosts. 
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Introduction 
Salmonellosis is a major cause of morbidity 
and mortality in both humans and animals. 
Although precise figures on disease burden are 
not available, it is estimated that globally there are 
approximately 3 billion human cases per year. The 
disease syndrome is predominantly gastroenteritis 
(diarrhoea or vomiting) but invasion from the gut 
has a major impact on mortality [1]. While vaccines 
are not widely utilised, either because there is no 
vaccine or because of cost, antibiotics remain the 
major tool for managing invasive disease [2]. 
However, most cases occur in resource-poor 
regions of the world where resistance to antibiotics 
and the cost of second-line agents are of major 
concern for the management of invasive 
salmonellosis. In this review we will describe the 
extent of resistance in the most common invasive 
Salmonella serovars: Salmonella enterica serovar 
Typhi and S. Paratyphi A. We will then go on to 
discuss the molecular mechanisms by which these 
two distinct but closely related pathogens have 
acquired and now share multi-drug resistance 
(MDR) to the antibiotics used for treatment. The 
main obstacle to current medical interventions is 
antibiotic resistance. 
 
Enteric fever: Typhoid fever and paratyphoid 
fever 
Typhoid fever is a systemic, febrile illness 
caused by the bacterium Salmonella enterica 
serovar Typhi (S. Typhi). Although, since the early 
20th century, the provision of good sanitation in 
Europe and the USA has led to a decline in the 
recorded disease burden, enteric fever remains a 
major public health problem in many parts of the 
world, mostly in developing countries. Estimates, 
such as 21.6 million cases resulting in 216,500 
deaths during the year 2000, are probably 
hopelessly inaccurate and the true burden, 
particularly in sub-Saharan Africa, is completely 
unknown.  Without appropriate treatment, up to 
20% of patients may develop and die of severe 
disease and life-threatening complications such as 
gastrointestinal perforation, toxaemia, meningitis 
or endocarditis [3]. Between 1 and 10% of typhoid 
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patients become chronic carriers; this is defined as 
excretion of S. Typhi in urine or stools for more 
than one year (reviewed in [2]).  
A very similar but classically less severe 
disease, paratyphoid fever, is caused 
predominantly by S. Paratyphi A. Although 
previously estimated to cause approximately a 
quarter of the incidence of typhoid fevers [4], 
studies from India and Nepal suggest that 
paratyphoid fever may contribute half of all cases 
of enteric fever (reviewed in [5]). Passive, 
community based, culture-confirmed surveillance 
shows that the proportion of enteric fever caused 
by S. Paratyphi A infection varies, from 14% in 
Indonesia to 64% in southern China [6]. 
 
Antibiotic resistance in Typhoidal Salmonellae 
Chloramphenicol was introduced for the 
treatment of typhoid fever in 1948. Although 
sporadic cases of chloramphenicol resistant 
typhoid fever were reported two years later, 
resistance to chloramphenicol took a long time to 
become established. The first reported outbreak of 
antibiotic resistant typhoid fever occurred in May 
1972 in Kerala, India. Chloramphenicol resistance 
was demonstrated to be plasmid-borne in the S. 
Typhi isolated during the outbreak.  In the same 
year, two other chloramphenicol resistant 
outbreaks were also documented, in Mexico and 
Vietnam, both caused by S. Typhi harbouring an 
IncH plasmid. The global spread of 
chloramphenicol resistant S. Typhi by the 1980s 
forced a change of treatment to co-trimoxazole or 
ampicillin in many regions. Multidrug resistance 
(MDR), defined as resistance to all first-line 
antimicrobials (ampicillin, co-trimoxazole, and 
chloramphenicol), emerged gradually in S. Typhi. 
The first reported MDR outbreak occurred in late 
1987 in China. In the next two years, there were 
reports of MDR S. Typhi strains from India, 
Pakistan and the Arabian Gulf. During the 
expansion of MDR S. Typhi, plasmids of 
incompatibility groups IncA, IncC and IncI were 
observed but failed to disseminate, whereas 
plasmids of the IncH group were seen repeatedly 
in outbreak cases and once acquired, conferred 
long-term resistance. Multidrug resistant S. Typhi 
strains harbouring IncHI1 plasmids are now 
globally distributed (reviewed in [1, 7]). 
With the emergence of MDR, the 
fluoroquinolone antibacterials became the 
treatment of choice for typhoid fever. Under this 
new selective pressure, an increase in resistance 
to fluoroquinolones [8] and a decline in MDR 
strains in some regions [9] were observed. More 
recently, the emergence of high-level ciprofloxacin 
resistance in S. Typhi [1] and S. Paratyphi A [10, 
11] has left treatment for resistant enteric fever 
dependent on third-generation cephalosporins and 
azithromycin [2]. While MDR S. Typhi strains have 
been isolated globally since the 1980s, S. 
Paratyphi A remained predominantly susceptible to 
antibiotics [12, 13]. In recent years however, there 
has been an increasing incidence of MDR S. 
Paratyphi A, particularly in Asia. In Nepal the MDR 
rate in S. Paratyphi A was higher (7%) than the 
rate in S. Typhi (5%) [14]; in North India, MDR S. 
Paratyphi A isolation was also increased [15]. For 
S. Paratyphi A infections imported into the USA, 
the only MDR cases were associated with a history 
of travel to Pakistan [16] In Europe, paratyphoid is 
almost entirely an imported disease but still acts as 
a reminder for the situation in endemic regions. In 
the UK, MDR S. Paratyphi A rose from 9% in 1999 
to 25% in 2001 in travellers, most of whom were 
returning from the Indian sub-continent [17]. 
 
Molecular basis of multidrug resistance – 
IncHI1 plasmids 
Plasmids of the Enterobacteriaceae are 
categorized into groups based upon their ability (or 
inability) to co-exist within the same bacterial cell. 
Plasmids of the same incompatibility (Inc) group 
are related, with similar replication mechanisms 
and regulatory circuits for essential plasmid 
functions; they cannot survive together in the same 
bacterial cell [18] and so are considered to be 
incompatible. More than 30 incompatibility groups 
have been described.  
The H incompatibility complex comprises two 
Inc groups, IncHI and IncHII, based on their similar 
H-pilus structure [19]. All IncH plasmids are large 
molecules with sizes of 150 kb or more and all are 
temperature sensitive for conjugative transfer [20]. 
Based on restriction digestion, DNA–DNA 
hybridization studies and incompatibility studies, 
the IncHI group of plasmids has been divided into 
three subgroups, IncHI1, IncHI2 and IncHI3. 
Although these groups are incompatible with each 
other, there is minimal homology over the whole of 
the plasmid [21, 22]. It seems, therefore, that only 
the replication apparatus is conserved between 
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these plasmids and that there must be a wide 
variety of genes associated with IncHI1 replicons. 
To find plasmids with a reduced rate of transfer at 
body temperature (37ºC) in a human restricted 
pathogen is unexpected. The efficiency is optimal 
at 22ºC to 30ºC which suggests that IncHI1 are 
potential vectors for the dissemination of genes 
among bacterial species in water and soil 
environments [23]. These plasmids have a wide 
host range which includes the Enterobacteriaceae 
and several Gram negative organisms of 
environmental significance. So why and how have 
these plasmids become established in typhoidal 
Salmonella?  
The complete nucleotide sequences of three 
IncHI1 plasmids, R27 (180kb), pHCM1 (218 kb) 
and pAKU1 (212 kb), have been determined [24-
26]. R27, the prototype of the IncHI1 plasmids, 
was first isolated in the UK from S. Typhimurium in 
1961. Very similar plasmids have subsequently 
been recovered from S. Typhi; pHCM1 originated 
from S. Typhi in Vietnam in 1993 and pAKU1 was 
from S. Paratyphi A strain AKU12601 from 
Pakistan in 2002. These three plasmids share a 
common backbone sequence (>99% identity at the 
DNA level) including 83% of the pAKU1 sequence. 
This suggests a close evolutionary relationship 
and also the spread of these MDR plasmids from 
one human restricted Salmonella serovar to 
another. 
 
R27, the prototypical IncHI1 plasmid 
The prototypical IncHI1 plasmid is R27 which 
encodes resistance to tetracycline only. This 
plasmid has been intensively studied for over 20 
years and, like all IncHI1 plasmids tested, R27 
possesses three replication initiation proteins: 
RepHI1A, RepHI1B and RepFIA-like [27, 28]. 
RepHI1A and RepHI1B have been shown to 
mediate plasmid replication and copy number 
control by binding of the Rep to the flanking repeat 
sequences (iterons) [29]. Both RepHI1A and 
RepHI1B are specific for IncHI1 plasmids. Minimal 
replicon analysis suggests that either of the two 
Rep proteins can efficiently replicate the entire 
plasmid but the RepFIA-like replication initiation 
protein of R27 is unable to stably replicate the 
entire plasmid under challenge conditions [28]. 
This RepFIA-like protein, however, confers one-
way compatibility between the HI1 and F plasmids. 
This is due to a short region of similarity in the 
essential replication protein of F (gene E) [30]. 
Conjugative transfer in IncHI1 plasmids is of 
special scientific interest, not only because the 
conjugative machinery has to accommodate the 
transfer of a very large plasmid, but also because 
of the way conjugation is regulated. There are two 
transfer regions (Tra1 and 2) which are essential 
for plasmid function but widely separated. With the 
full sequence of R27 we now know that the Tra1 
region is located between the coordinates 98 and 
117 kb and contains 14 predicted coding 
sequences (CDSs), only nine of which encode 
essential transfer genes. The CDSs are organised 
into three operons: H, R and F [31, 32]. The origin 
of transfer (oriT) was also identified in this region, 
between the H and R operons. The R and F 
operons encode the mating pair formation (Mpf) 
components and show sequence homology to the 
IncF transfer system. The H operon contains 
genes encoding for relaxosome proteins (traJ and 
traI), the coupling protein (traG) and other proteins 
not essential for transfer. The coupling protein was 
shown to be ancestrally related (low identity) to 
that of IncP plasmids. The Tra2 region is sixty-
three kilobases away from Tra1, spanning over 36 
kb and containing 28 CDSs. Except for four CDSs 
involved in partition function, the remaining CDSs 
are arranged into 3 operons encoding for Mpf/H-
pilus components (AC and AN operons) and entry 
exclusion proteins (Z operon) [31] [33]. A total of 
11 genes in this region have been demonstrated 
by mutational and genetic analysis to be essential 
for conjugative transfer [34]. Similar to Tra1, this 
region also exhibits a mosaic of IncF-related (Mpf 
genes) and IncP-related (trhA and trhP) 
sequences. In summary, the conjugative transfer 
system of R27 consists of 20 essential genes 
located in 2 separate regions and the Mpf system 
shares a common ancestry with the IncF lineage. 
The relaxosome, pilin and peptidase genes show 
closer relatedness to IncP plasmids. 
 
Temperature dependent conjugation and H-NS 
An interesting phenotype seen with R27 and 
R27-like plasmids is that they regulate their own 
conjugative transfer in a temperature-dependent 
manner. This has implications for transmission and 
persistence of the resistance phenotype in the 
typhoidal salmonella population. The 
thermoregulation of transfer is a multi-level 
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regulatory process involving the thermo-dependent 
mating pair formation, the global regulatory protein 
H-NS and a thermo-modulator Hha. The H pilus is 
synthesized at an optimal temperature of 27ºC by 
extrusion from the cell surface. At 37ºC, the 
morphology of H pili remains stable whilst the 
formation of mating aggregates is inhibited [35]. 
No pili can be observed by transmission electron 
microscopy at 37ºC, in agreement with expression 
data from other studies. H-NS-like and Hha-like 
proteins on R27 repress transcription of several 
CDSs in both Tra1 and Tra2 regions at the non-
permissive temperatures, (20-33ºC). Band shift 
assays suggest the inhibition mechanism of H-NS 
involves interaction with the promoter regions from 
Tra1 and Tra2 and with the origin of replication 
(oriT) sequence. The presence of Hha facilitates 
the generation of higher-order hetero-oligomers of 
H-NS that interact with DNA and may alter, in a 
very subtle way, the expression of chromosomal 
genes of the bacterial host for these plasmids [36]. 
 
IncHI1 plasmids in S. Typhi 
The stable maintenance of IncHI1 plasmids in 
S. Typhi occurred throughout the development of 
antibiotic resistance in S. Typhi. The first reported 
S. Typhi harbouring an IncH plasmid was resistant 
to chloramphenicol, tetracycline, streptomycin, and 
sulphonamides and was isolated during a large 
outbreak of resistant typhoid fever in Mexico City 
[37]. Two other outbreaks of IncHI1 carrying S. 
Typhi also began in the same year in Vietnam and 
India. The plasmids from the three outbreaks were 
all of the IncHI1 group and all the same size, but 
they differed in the phenotype conferred to the 
bacterial host in resistance to mercury and ability 
to utilise citrate [21].  The spread of 
chloramphenicol-resistant S. Typhi forced the 
change in treatment to either co-trimoxazole or 
ampicillin in several regions, including India and 
Vietnam [38]. This then led to the emergence of 
multiple drug resistant (MDR) S. Typhi and in 1988 
in Kashmir the first reported MDR outbreak of 
typhoid fever occurred [39]. Multidrug resistant S. 
Typhi was also reported from Egypt in the same 
year [40], Shanghai in 1988-1989 [41], Qatar in 
1988 [42] and eastern India in 1989 [43]. Several 
isolates from these regions were shown to carry 
plasmids of high molecular weights (150kb to 
185kb). The MDR S. Typhi spread globally and by 
1998 IncHI1 plasmids could be isolated from MDR 
S. Typhi worldwide [44].  
 
The movement of IncHI1 plasmid into S. 
Paratyphi A 
Plasmid-mediated multidrug resistance was, 
until recently, uncommon in S. Paratyphi A. 
However MDR S. Paratyphi A isolates in 
Bangladesh and Karachi have now been shown to 
harbour a large transferable plasmid of 140 MDa 
(~212 kb). Recently, a 212-kb plasmid of IncHI1 
isolated from a S. Paratyphi A, identified at the 
Aga Khan University Hospital in Karachi, Pakistan, 
was fully sequenced and annotated [26]. 
Sequence comparison showed high levels of 
identity of this plasmid (pAKU1) with the two other 
IncHI1 plasmids, pHCM1 and R27. A shared 
IncHI1 backbone of 164.4 kb was identified, 
including the IncHI1 incompatibility locus, the three 
replicons (RepHI1A, RepHI1B and RepFIA) and 
genes involved in the core plasmid function of 
replication, maintenance and conjugative transfer 
as well as many hypothetical genes.  
The pAKU1 plasmid was among 67 PCR-
determined IncHI1 plasmids (out of 68 MDR S. 
Paratyphi A isolates) from Pakistan in 2002-2004. 
The high prevalence of IncHI1 plasmids in this 
area strongly suggests a successful jump of IncHI1 
plasmids into the S. Paratyphi A population. 
Further information is needed to assert whether 
these IncHI1-bearing S. Paratyphi A isolates are 
the result of a clonal expansion of a single 
successful combination of S. Paratyphi A 
background and IncHI1 plasmid, or whether IncHI1 
plasmids have successfully invaded multiple 
clones of S. Paratyphi A in the population. The 
next stage of this research will be to type the 
background strains from a global collection of 
MDR S. Paratyphi A.  
 
Plasmid evolution 
 Acquiring a large plasmid (such as IncHI1) is 
commonly believed to impose a fitness burden on 
the bacterial host. However, it has been shown in 
the laboratory environment that co-evolution 
occurs in plasmid-harbouring bacteria, resulting in 
increased fitness over the plasmid-free ancestor 
[45] [46]. The evolved plasmids also confer a 
fitness advantage to new cells, suggesting that the 
phenomenon is plasmid encoded [46]. If this 
adaptation occurs under natural conditions, then 
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once a conjugative plasmid becomes established 
in a bacterial population, it will remain even if the 
original selection (antibiotic usage) is removed. 
Furthermore, the acquisition of a newly adapted 
plasmid, as seen in S.  Paratyphi A, might help the 
new host bacterium to spread due to a fitness 
advantage, other than resistance, thus amplifying 
the plasmid. 
Although IncHI1 plasmids are not commonly 
found in organisms other than S. Typhi, their 
thermo-sensitive transmission and relatively wide 
host range suggest an origin from soil bacteria. 
Chloramphenicol resistant outbreaks in 1972, the 
subsequent global spread of IncHI1 plasmids in S. 
Typhi and their recent acquisition by S. Paratyphi 
A may represent the situation suggested above. 
Studies looking at the natural evolution of clinically 
important plasmids have been predominantly 
phenotypic and a definitive link between enhanced 
bacterial fitness and acquired antibiotic resistance 
has proved elusive.  In the genomic era, however, 
if global strain collections from countries where 
antibiotic resistance is endemic can be analysed 
using data derived from the new sequencing 
technologies such as 454 and Solexa, the linking 
of plasmid-borne genes to enhanced bacterial 
fitness should be feasible, if such a link exists [47], 
as well as to a reduction in biological cost [48]. 
 
Figure 1. Genetic map of IncHI1 plasmid pHCM1.  
Genetic map of pHCM1 with highlighted features: yellow – transfer 
regions; blue – other plasmid biology functions (replication, partition 
and post-segregation killing); green – mobile elements; red – resistant 
genes/operons; and grey – regions acquired by pHCM1 but not found 
in the prototype plasmid R27. 
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Conclusion 
The IncHI1 plasmids found in S. Typhi today 
have been co-evolving with their bacterial host at 
least since the 1970s. They are still present in 
many areas of the world, even though resistance 
to the antibiotics of choice for enteric fever (the 
fluoroquinolones) is not encoded on IncHI1 
plasmids. The plasmids (but not always the 
resistance phenotype) are stably maintained in 
antibiotic-free laboratory media. These large 
plasmids confer no detectable cost to S. Typhi. 
This easy co-existence requires the integration of 
plasmid and bacterial gene expression regulation 
networks. A plasmid encoded nucleoid-associated 
protein (H-NS-like protein) confers a stealth 
mechanism through which A+T-rich R27-like 
plasmids can enter Salmonella hosts with minimal 
impact on global gene expression patterns [48]. 
This strategy has the effect of smoothing the initial 
entry of extra-chromosomal genetic material, 
mediating the process of adaptation and 
integration of this new element into the regulatory 
network. There is, however, something deeper, 
some subtle regulatory balance, or imbalance, 
which confers an advantage associated with the 
presence of an IncHI1 plasmid. The possession of 
an R27-like IncHI1 plasmid was shown to increase 
the level of survival inside monocytic cell lines in S. 
Typhimurium [48] and to allow higher levels of 
bacteraemia for S. Typhi during typhoid fever [49]. 
This suggests a role of this plasmid in the 
enhancement of bacterial survival and 
multiplication in vivo. 
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